Category: Benevolent AI

  • BenevolentAI, AstraZeneca AI-based drug discovery collaboration achieves third milestone

    BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the London-based research firm. This is the third novel target from the duo’s collaboration identified using the Benevolent Platform across two disease areas – IPF and chronic kidney […]